XTX Topco Ltd Takes $515,000 Position in BioLife Solutions, Inc. $BLFS

XTX Topco Ltd acquired a new stake in BioLife Solutions, Inc. (NASDAQ:BLFS) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 23,928 shares of the medical equipment provider’s stock, valued at approximately $515,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Commonwealth of Pennsylvania Public School Empls Retrmt SYS bought a new stake in BioLife Solutions during the second quarter worth approximately $205,000. Comerica Bank increased its holdings in shares of BioLife Solutions by 5.2% in the first quarter. Comerica Bank now owns 15,024 shares of the medical equipment provider’s stock valued at $343,000 after buying an additional 746 shares in the last quarter. Forum Private Client Group LLC acquired a new stake in shares of BioLife Solutions during the 2nd quarter valued at $232,000. Royal Bank of Canada boosted its stake in shares of BioLife Solutions by 762.8% during the 1st quarter. Royal Bank of Canada now owns 698,251 shares of the medical equipment provider’s stock worth $15,948,000 after acquiring an additional 617,320 shares in the last quarter. Finally, State of Alaska Department of Revenue grew its holdings in shares of BioLife Solutions by 10.2% in the 2nd quarter. State of Alaska Department of Revenue now owns 22,096 shares of the medical equipment provider’s stock worth $475,000 after acquiring an additional 2,048 shares during the last quarter. 93.24% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $32.00 price target on shares of BioLife Solutions in a research report on Monday, November 24th. Zacks Research upgraded shares of BioLife Solutions from a “hold” rating to a “strong-buy” rating in a report on Friday, November 7th. Wall Street Zen lowered shares of BioLife Solutions from a “buy” rating to a “hold” rating in a report on Sunday, November 30th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioLife Solutions in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $31.20.

Insider Transactions at BioLife Solutions

In other BioLife Solutions news, Director Amy Duross sold 4,523 shares of the company’s stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $24.51, for a total value of $110,858.73. Following the transaction, the director directly owned 25,687 shares of the company’s stock, valued at $629,588.37. This represents a 14.97% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Joydeep Goswami sold 1,666 shares of the business’s stock in a transaction that occurred on Friday, October 24th. The shares were sold at an average price of $28.99, for a total value of $48,297.34. Following the completion of the sale, the director directly owned 44,986 shares of the company’s stock, valued at approximately $1,304,144.14. The trade was a 3.57% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 905,727 shares of company stock valued at $25,497,734. Corporate insiders own 2.20% of the company’s stock.

BioLife Solutions Stock Performance

BioLife Solutions stock opened at $25.83 on Friday. BioLife Solutions, Inc. has a twelve month low of $19.10 and a twelve month high of $29.62. The firm has a market cap of $1.24 billion, a PE ratio of -368.95 and a beta of 1.93. The firm’s 50 day moving average price is $26.54 and its two-hundred day moving average price is $24.34.

BioLife Solutions Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.